| [1] |
Pan K, Farrukh H, Chittepu VCSR, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy[J]. J Exp Clin Cancer Res, 2022, 41(1): 119.
|
| [2] |
Zhang BL, Qin DY, Mo ZM, et al. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors[J]. Sci China Life Sci, 2016, 59(4): 340-348.
|
| [3] |
Martinez M,Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment[J]. Front Immunol, 2019, 10: 128.
|
| [4] |
Fang J, Nakamura H,Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect[J]. Adv Drug Deliv Rev, 2011, 63(3): 136-151.
|
| [5] |
Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors[J]. Cancer Res, 2014, 74(24): 7168-7174.
|
| [6] |
Kankeu Fonkoua LA, Sirpilla O, Sakemura R, et al. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities[J]. Mol Ther Oncolytics, 2022, 25: 69-77.
|
| [7] |
Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities[J]. Stem Cell Res Ther, 2021, 12(1): 81.
|
| [8] |
Goydel RS, Rader C. Antibody-based cancer therapy[J]. Oncogene, 2021, 40(21): 3655-3664.
|
| [9] |
Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies[J]. J Hematol Oncol, 2020, 13(1): 45.
|
| [10] |
Caratelli S, Arriga R, Sconocchia T, et al. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab[J]. Int J Cancer, 2020, 146(1): 236-247.
|
| [11] |
Marin-Acevedo JA, Kimbrough EO, Lou YY. Next generation of immune checkpoint inhibitors and beyond[J]. J Hematol Oncol, 2021, 14(1): 45.
|
| [12] |
Grosser R, Cherkassky L, Chintala N, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors[J]. Cancer Cell, 2019, 36(5): 471-482.
|
| [13] |
Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab[J]. Cancer Discov, 2021, 11(11): 2748-2763.
|
| [14] |
Yamaguchi Y, Gibson J, Ou K, et al. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages[J]. J Immunother Cancer, 2022, 10(6): e004400.
|
| [15] |
Yang J, Yan J,Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity[J]. Front Immunol, 2018, 9: 978.
|
| [16] |
Bocca P, di Carlo E, Caruana I, et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model[J]. Oncoimmunology, 2017, 7(1): e1378843.
|
| [17] |
Guedan S, Alemany R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge[J]. Front Immunol, 2018, 9: 2460.
|
| [18] |
Tang XY, Ding YS, Zhou T, et al. Tumor-tagging by oncolytic viruses: a novel strategy for CAR-T therapy against solid tumors[J]. Cancer Lett, 2021, 503: 69-74.
|
| [19] |
Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells[J]. J Immunother Cancer, 2017, 5(1): 90.
|
| [20] |
Watanabe K, Luo YP, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses[J].JCI Insight, 2018, 3(7): e99573.
|
| [21] |
Wang GQ, Zhang ZL, Zhong KH, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma[J]. Mol Ther, 2023, 31(1): 134-153.
|
| [22] |
Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies[J]. J Hematol Oncol, 2021, 14(1): 63.
|
| [23] |
Porter CE, Rosewell Shaw A, Jung Y, et al. Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors[J]. Mol Ther, 2020, 28(5): 1251-1262.
|
| [24] |
Wenthe J, Naseri S, Labani-Motlagh A, et al. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy[J]. Cancer Immunol Immunother, 2021, 70(10): 2851-2865.
|
| [25] |
Shemesh CS, Hsu JC, Hosseini I, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities[J]. Mol Ther, 2021, 29(2): 555-570.
|
| [26] |
Liu J, Fu MY, Wang MN, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress[J]. J Hematol Oncol, 2022, 15(1): 28.
|
| [27] |
Matsuo K, Yoshie O, Kitahata K, et al. Recent progress in dendritic cell-based cancer immunotherapy[J]. Cancers (Basel), 2021, 13(10): 2495.
|
| [28] |
Wu MR, Zhang LT, Zhang HZ, et al. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia[J]. Cytotherapy, 2019, 21(6): 659-670.
|
| [29] |
Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors[J]. Science, 2020, 367(6476): 446-453.
|
| [30] |
Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future[J]. Mol Cell Proteomics, 2021, 20: 100022.
|
| [31] |
Ma LY, Dichwalkar T, Chang JYH, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor[J]. Science, 2019, 365(6449): 162-168.
|
| [32] |
Shi Y, Lammers T. Combining nanomedicine and immunotherapy[J]. Acc Chem Res, 2019, 52(6): 1543-1554.
|
| [33] |
Abdalla AME, Xiao L, Miao Y, et al. Nanotechnology promotes genetic and functional modifications of therapeutic T cells against cancer[J]. Adv Sci (Weinh), 2020, 7(10): 1903164.
|
| [34] |
Duan XP, Chan C, Lin WB. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy[J]. Angewandte Chemie Int Ed, 2019, 58(3): 670-680.
|
| [35] |
Chen Q, Hu QY, Dukhovlinova E, et al. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells[J]. Adv Mater, 2019, 31(23): e1900192.
|
| [36] |
Miao L, Li JJ, Liu Q, et al. Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer[J]. ACS Nano, 2017, 11(9): 8690-8706.
|
| [37] |
Lian HP, Ma S, Zhao DY, et al. Cytokine therapy combined with nanomaterials participates in cancer immunotherapy[J]. Pharmaceutics, 2022, 14(12): 2606.
|
| [38] |
Jiang JY, Zhang YD, Peng K, et al. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy[J]. Acta Biomater, 2017, 61: 114-123.
|
| [39] |
Sun ZC, Li RT, Shen Y, et al. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors[J]. J Hematol Oncol, 2022, 15(1): 29.
|
| [40] |
Zang H, Siddiqui M, Gummuluru S, et al. Ganglioside-functionalized nanoparticles for chimeric antigen receptor T-cell activation at the immunological synapse[J]. ACS Nano, 2022, 16(11): 18408-18420.
|
| [41] |
Alhallak K, Sun J, Wasden K, et al. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy[J]. Leukemia, 2021, 35(8): 2346-2357.
|
| [42] |
Zuo YH, Zhao XP, Fan XX. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor[J]. Pharmacol Res, 2022, 184: 106454.
|
| [43] |
Grosskopf AK, Labanieh L, Klysz DD, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors[J]. Sci Adv, 2022, 8(14): eabn8264.
|
| [44] |
Hu QY, Li HJ, Archibong E, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets[J]. Nat Biomed Eng, 2021, 5(9): 1038-1047.
|
| [45] |
Cho KJ, Cho YE, Kim J. Locoregional lymphatic delivery systems using nanoparticles and hydrogels for anticancer immunotherapy[J]. Pharmaceutics, 2022, 14(12): 2752.
|
| [46] |
Wen R, Umeano AC, Kou Y, et al. Nanoparticle systems for cancer vaccine[J]. Nanomedicine (London), 2019, 14(5): 627-648.
|
| [47] |
Chen WQ, Jiang MX, Yu WJ, et al. CpG-based nanovaccines for cancer immunotherapy[J]. Int J Nanomedicine, 2021, 16: 5281-5299.
|
| [48] |
Chen H, Fan Y, Hao XX, et al. Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector[J]. J Mater Chem B, 2020, 8(23): 5052-5063.
|
| [49] |
Chen JJ, Ye ZF, Huang CF, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response[J]. Proc Natl Acad Sci U S A, 2022, 119(34): e2207841119.
|
| [50] |
Ma S, Li XC, Wang XY, et al. Current progress in CAR-T cell therapy for solid tumors[J]. Int J Biol Sci, 2019, 15(12): 2548-2560.
|
百度学术
下载:
